Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

La Jolla identifies target of antibodies responsible for life-threatening autoimmune disorder

Sep. 17, 1998

Medical device for rheumatoid arthritis scheduled for October advisory panel review

Sep. 17, 1998

Advisory committee unanimously recommends approval for Enbrel

Sep. 17, 1998

Viragen acquires stake in Inflammatics; adds LeukoVAX to pipeline

Sep. 15, 1998

FDA approves, HMR begins shipping new treatment for adult rheumatoid arthritis

Sep. 14, 1998

Inhibitors of ICE activity described by Vertex

Sep. 14, 1998

Merck & Co. discovers another potent and selective COX-2 inhibitor

Sep. 11, 1998

Merck Frosst reveals discoveries in the field of COX-2 inhibitors at ACS meeting

Sep. 11, 1998

Kotobuki selects development candidate from novel series with selectivity for COX-2

Sep. 11, 1998

Merck's COX-2 inhibitor Vioxx shown safe and effective in clinical trials

Sep. 10, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...